{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:29:50Z","timestamp":1793294990304,"version":"4.5.0"},"reference-count":133,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T00:00:00Z","timestamp":1625616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>The glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide is the most recently approved agent of this drug class, and the only GLP-1RA currently available as both subcutaneous and oral formulation. While GLP-1RAs effectively improve glycemic control and cause weight loss, potential safety concerns have arisen over the years. For semaglutide, such concerns have been addressed in the extensive phase 3 registration trials including cardiovascular outcome trials for both subcutaneous (SUSTAIN: Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) and oral (PIONEER: Peptide InnOvatioN for the Early diabEtes tReatment) semaglutide and are being studied in further trials and registries, including real world data studies. In the current review we discuss the occurrence of adverse events associated with semaglutide focusing on hypoglycemia, gastrointestinal side effects, pancreatic safety (pancreatitis and pancreatic cancer), thyroid cancer, gallbladder events, cardiovascular aspects, acute kidney injury, diabetic retinopathy (DRP) complications and injection-site and allergic reactions and where available, we highlight potential underlying mechanisms. Furthermore, we discuss whether effects are specific for semaglutide or a class effect. We conclude that semaglutide induces mostly mild-to-moderate and transient gastrointestinal disturbances and increases the risk of biliary disease (cholelithiasis). No unexpected safety issues have arisen to date, and the established safety profile for semaglutide is similar to that of other GLP-1RAs where definitive conclusions for pancreatic and thyroid cancer cannot be drawn at this point due to low incidence of these conditions. Due to its potent glucose-lowering effect, patients at risk for deterioration of existing DRP should be carefully monitored if treated with semaglutide, particularly if also treated with insulin. Given the beneficial metabolic and cardiovascular actions of semaglutide, and the low risk for severe adverse events, semaglutide has an overall favorable risk\/benefit profile for patient with type 2 diabetes.<\/jats:p>","DOI":"10.3389\/fendo.2021.645563","type":"journal-article","created":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T13:16:16Z","timestamp":1625663776000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":269,"title":["Safety of Semaglutide"],"prefix":"10.3389","volume":"12","author":[{"given":"Mark M.","family":"Smits","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dani\u00ebl H.","family":"Van Raalte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,7]]},"reference":[{"key":"B1","unstructured":"IDF Diabetes Atlas 20192019"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00034.2006","article-title":"The Physiology of Glucagon-Like Peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12593","article-title":"Gastrointestinal Actions of GLP-1 Based Therapies: Glycaemic Control Beyond the Pancreas","volume":"18","author":"Smits","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14008","article-title":"Efficacy and Tolerability of Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: A Systematic Review and Network Meta-Analysis","volume":"22","author":"Hussein","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-019-00826-0","article-title":"Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Feature","volume":"39","author":"Lyseng-Williamson","year":"2019","journal-title":"Clin Drug Investig"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.02.018","article-title":"Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1-Based Therapies","volume":"141","author":"Elashoff","year":"2011","journal-title":"Gastroenterology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00155","article-title":"The Discovery and Development of Liraglutide and Semaglutid","volume":"10","author":"Knudsen","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"eaar7047","DOI":"10.1126\/scitranslmed.aar7047","article-title":"Transcellular Stomach Absorption of a Derivatized Glucagon-Like Peptide-1 Receptor Agonist","volume":"10","author":"Buckley","year":"2018","journal-title":"Sci Transl Med"},{"key":"B9","first-page":"1","article-title":"Similar Efficacy and Gastrointestinal Tolerability Versus Exposure for Oral and Subcutaneous Semaglutide","volume-title":"Diabetologia","author":"Overgaard","year":"2019"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and Safety of Once-Weekly Semaglutide Monotherapy Versus Placebo in Patients With Type 2 Diabetes (SUSTAIN 1): A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multinational, Multicentre Phase 3a Trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30092-X","article-title":"Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin as an Add-on to Metformin, Thiazolidinediones, or Both, in Patients With Type 2 Diabetes (SUSTAIN 2): A 56-Week, Double-Blind, Phase 3a, Randomised Trial","volume":"5","author":"Ahr\u00e9n","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13082","article-title":"Safety and Efficacy of Semaglutide Once Weekly vs Sitagliptin Once Daily, Both as Monotherapy in J Apanese People With Type 2 Diabetes","volume":"20","author":"Seino","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13218","article-title":"Safety and Efficacy of Once-Weekly Semaglutide vs Additional Oral Antidiabetic Drugs in Japanese People With Inadequately Controlled Type 2 Diabetes: A Randomized Trial","volume":"20","author":"Kaku","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0749","article-title":"PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabete","volume":"42","author":"Aroda","year":"2019","journal-title":"Diabetes Care"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0883","article-title":"Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Tria","volume":"42","author":"Rodbard","year":"2019","journal-title":"Diabetes Care"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1001\/jama.2019.2942","article-title":"Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylure","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"B17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","article-title":"Oral Semaglutide Versus Subcutaneous Liraglutide and Placebo in Type 2 Diabetes (PIONEER 4): A Randomised, Double-Blind, Phase 3a Trial","volume":"394","author":"Pratley","year":"2019","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30192-5","article-title":"Efficacy and Safety of Oral Semaglutide in Patients With Type 2 Diabetes and Moderate Renal Impairment (PIONEER 5): A Placebo-Controlled, Randomised, Phase 3a Trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral Semaglutide and Cardiovascular Outcomes in Patients With Type 2 Diabete","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30194-9","article-title":"Efficacy and Safety of Oral Semaglutide With Flexible Dose Adjustment Versus Sitagliptin in Type 2 Diabetes (PIONEER 7): A Multicentre, Open-Label, Randomised, Phase 3a Trial","volume":"7","author":"Pieber","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0898","article-title":"Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Tria","volume":"42","author":"Zinman","year":"2019","journal-title":"Diabetes Care"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-0417","article-title":"Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Tria","volume":"41","author":"Ahmann","year":"2018","journal-title":"Diabetes Care"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30075-9","article-title":"Dose-Response, Efficacy, and Safety of Oral Semaglutide Monotherapy in Japanese Patients With Type 2 Diabetes (PIONEER 9): A 52-Week, Phase 2\/3a, Randomised, Controlled Trial","volume":"8","author":"Yamada","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/S2213-8587(20)30074-7","article-title":"Safety and Efficacy of Oral Semaglutide Versus Dulaglutide in Japanese Patients With Type 2 Diabetes (PIONEER 10): An Open-Label, Randomised, Active-Controlled, Phase 3a Trial","volume":"8","author":"Yabe","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14232","article-title":"Efficacy and Safety of Once-Weekly Semaglutide vs Once-Daily Sitagliptin as Add-on to Metformin in Patients With Type 2 Diabetes (SUSTAIN China): A 30-Week Double-Blind, Phase 3a, Randomised Trial","volume":"23","author":"Ji","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30085-2","article-title":"Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Insulin Glargine as Add-on to Metformin (With or Without Sulfonylureas) in Insulin-Naive Patients With Type 2 Diabetes (SUSTAIN 4): A Randomised, Open-Label, Parallel-Group, Multicentre, Mul","volume":"5","author":"Aroda","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00070","article-title":"Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Tria","volume":"103","author":"Rodbard","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients With Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide Versus Dulaglutide Once Weekly in Patients With Type 2 Diabetes (SUSTAIN 7): A Randomised, Open-Label, Phase 3b Trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30311-0","article-title":"Efficacy and Safety of Once-Weekly Semaglutide Versus Daily Canagliflozin as Add-on to Metformin in Patients With Type 2 Diabetes (SUSTAIN 8): A Double-Blind, Phase 3b, Randomised Controlled Trial","volume":"7","author":"Lingvay","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30066-X","article-title":"Semaglutide Once Weekly as Add-on to SGLT-2 Inhibitor Therapy in Type 2 Diabetes (SUSTAIN 9): A Randomised, Placebo-Controlled Trial","volume":"7","author":"Zinman","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2019.101117","article-title":"Efficacy and Safety of Once-Weekly Semaglutide 1.0 Mg vs Once-Daily Liraglutide 1.2 Mg as Add-on to 1\u20133 Oral Antidiabetic Drugs in Subjects With Type 2 Diabetes (SUSTAIN 10)","volume":"46","author":"Capehorn","year":"2020","journal-title":"Diabetes Metab"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0677-1","article-title":"Irie S. A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subject","volume":"35","author":"Ikushima","year":"2018","journal-title":"Adv Ther"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0728-4","article-title":"Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects With Type 2 Diabete","volume":"58","author":"Granhall","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13422","article-title":"Effect of Once-Weekly Semaglutide on the Counterregulatory Response to Hypoglycaemia in People With Type 2 Diabetes: A Randomized, Placebo-Controlled, Double-Blind, Crossover Trial","volume":"20","author":"Korsatko","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14117","article-title":"Semaglutide Once Weekly in People With Type 2 Diabetes: Real-World Analysis of the Canadian LMC Diabetes Registry ( SPARE Study)","volume":"22","author":"Brown","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"B37","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s13300-018-0535-9","article-title":"Reviriego J. A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabete","volume":"10","author":"Romera","year":"2019","journal-title":"Diabetes Ther"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2017.14752","article-title":"Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabete","volume":"318","author":"Davies","year":"2017","journal-title":"JAMA"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-021-01015-z","article-title":"Real-World Clinical Experience of Semaglutide in Secondary Care Diabetes: A Retrospective Observational Stud","volume":"12","author":"Williams","year":"2021","journal-title":"Diabetes Ther"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-020-00984-x","article-title":"Real-World Effectiveness Analysis of Switching From Liraglutide or Dulaglutide to Semaglutide in Patients With Type 2 Diabetes Mellitus: The Retrospective REALISE-DM Stud","volume":"12","author":"Jain","year":"2021","journal-title":"Diabetes Ther"},{"key":"B41","doi-asserted-by":"publisher","first-page":"32","DOI":"10.2337\/diaclin.32.1.32","article-title":"Optimizing the Care of Patients With Type 2 Diabetes Using Incretin-Based Therapy: Focus on GLP-1 Receptor Agonist","volume":"32","author":"Shomali","year":"2014","journal-title":"Clin Diabetes"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2010.03085.x","article-title":"Prophylactic Use of Anti-Emetic Medications Reduced Nausea and Vomiting Associated With Exenatide Treatment: A Retrospective Analysis of an Open-Label, Parallel-Group, Single-Dose Study in Healthy Subjects","volume":"27","author":"Ellero","year":"2010","journal-title":"Diabetes Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12824","article-title":"Occurrence of Nausea, Vomiting and Diarrhoea Reported as Adverse Events in Clinical Trials Studying Glucagon-Like Peptide-1 Receptor Agonists: A Systematic Analysis of Published Clinical Trials","volume":"19","author":"Bettge","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.regpep.2008.07.003","article-title":"Effect of Exenatide on Gastric Emptying and Relationship to Postprandial Glycemia in Type 2 Diabetes","volume":"151","author":"Linnebjerg","year":"2008","journal-title":"Regul Pept"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.81.1.8550773","article-title":"Gastric Emptying, Glucose Responses, and Insulin Secretion After a Liquid Test Meal: Effects of Exogenous Glucagon-Like Peptide-1 (GLP-1)-(7-36) Amide in Type 2 (Noninsulin-Dependent) Diabetic Patients","volume":"81","author":"Willms","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107768","article-title":"Corrination of a GLP-1 Receptor Agonist for Glycemic Control Without Emesi","volume":"31","author":"Borner","year":"2020","journal-title":"Cell Rep"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1159\/000094334","article-title":"Glucagon-Like Peptide-1 is Involved in Sodium and Water Homeostasis in Humans","volume":"73","author":"Gutzwiller","year":"2006","journal-title":"Digestion"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e3181d9d87a","article-title":"Effects of Exogenous Glucagon-Like Peptide-1 on Gastric Emptying and Glucose Absorption in the Critically Ill: Relationship to Glycemia","volume":"38","author":"Deane","year":"2010","journal-title":"Crit Care Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.112.246207","article-title":"Exenatide, a Glucagon-Like Peptide-1 Receptor Agonist, Acutely Inhibits Intestinal Lipoprotein Production in Healthy Humans","volume":"32","author":"Xiao","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1177\/2050640620925968","article-title":"Liraglutide Accelerates Colonic Transit in People With Type 1 Diabetes and Polyneuropathy: A Randomised, Double-Blind, Placebo-Controlled Trial","volume":"8","author":"Wegeberg","year":"2020","journal-title":"United Eur Gastroenterol J"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2013.149","article-title":"Tolerability of Nausea and Vomiting and Associations With Weight Loss in a Randomized Trial of Liraglutide in Obese, non-Diabetic Adults","volume":"38","author":"Lean","year":"2014","journal-title":"Int J Obes"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13353","article-title":"Semaglutide Induces Weight Loss in Subjects With Type 2 Diabetes Regardless of Baseline BMI or Gastrointestinal Adverse Events in the SUSTAIN 1 to 5 Trials","volume":"20","author":"Ahr\u00e9n","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e001706","DOI":"10.1136\/bmjdrc-2020-001706","article-title":"Superior Weight Loss With Once-Weekly Semaglutide Versus Other Glucagon-Like Peptide-1 Receptor Agonists is Independent of Gastrointestinal Adverse Events","volume":"8","author":"Lingvay","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01376.x","article-title":"A Cohort Study of Acute Pancreatitis in Relation to Exenatide Use","volume":"13","author":"Dore","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12230","article-title":"A Prospective, Claims-Based Assessment of the Risk of Pancreatitis and Pancreatic Cancer With Liraglutide Compared to Other Antidiabetic Drugs","volume":"16","author":"Funch","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-0482","article-title":"Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin: A Retrospective Observational Pharmacy Claims Analysis","volume":"33","author":"Garg","year":"2010","journal-title":"Diabetes Care"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(13)70147-5","article-title":"Incretin Therapies and Risk of Hospital Admission for Acute Pancreatitis in an Unselected Population of European Patients With Type 2 Diabetes: A Case-Control Study","volume":"2","author":"Giorda","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g2366","article-title":"Incretin Treatment and Risk of Pancreatitis in Patients With Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis of Randomised and Non-Randomised Studies","volume":"348","author":"Li","year":"2014","journal-title":"BMJ"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2012.03652.x","article-title":"Relative Risk of Acute Pancreatitis in Initiators of Exenatide Twice Daily Compared With Other Anti-Diabetic Medication: A Follow-Up Study","volume":"29","author":"Wenten","year":"2012","journal-title":"Diabetes Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2013.2720","article-title":"Glucagonlike Peptide 1-Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus: A Population-Based Matched Case-Control Study","volume":"173","author":"Singh","year":"2013","journal-title":"JAMA Intern Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-1755","article-title":"Increased Risk of Acute Pancreatitis and Biliary Disease Observed in Patients With Type 2 Diabetes: A Retrospective Cohort Study","volume":"32","author":"Noel","year":"2009","journal-title":"Diabetes Care"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2019-00033","article-title":"The Incremental Risk of Pancreatic Cancer According to Fasting Glucose Levels: Nationwide Population-Based Cohort Stud","volume":"104","author":"Koo","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02223-6","article-title":"GLP-1 Receptor Agonists and Pancreatic Safety Concerns in Type 2 Diabetic Patients: Data From Cardiovascular Outcome Trials","volume":"68","author":"Cao","year":"2020","journal-title":"Endocrine"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.4158\/EP11290.OR","article-title":"Elevated Amylase and Lipase Levels in Patients Using Glucagonlike Peptide-1 Receptor Agonists or Dipeptidyl-Peptidase-4 Inhibitors in the Outpatient Setting","volume":"18","author":"Lando","year":"2012","journal-title":"Endocr Pract"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2013.03.034","article-title":"A Low-Grade Increase of Serum Pancreatic Exocrine Enzyme Levels by Dipeptidyl Peptidase-4 Inhibitor in Patients With Type 2 Diabetes","volume":"100","author":"Tokuyama","year":"2013","journal-title":"Diabetes Res Clin Pract"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13160","article-title":"Acute Plasma Amylase Increase After Glucagon-Like Peptide -1 Receptor Agonist Exenatide Administration in Type 2 Diabetes","volume":"34","author":"Smits","year":"2017","journal-title":"Diabetes Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-2684","article-title":"Impact of Liraglutide on Amylase, Lipase, and Acute Pancreatitis in Participants With Overweight\/Obesity and Normoglycemia, Prediabetes, or Type 2 Diabetes: Secondary Analyses of Pooled Data From the SCALE Clinical\u00a0Development Progra","volume":"40","author":"Steinberg","year":"2017","journal-title":"Diabetes Care"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-2747","article-title":"Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Tria","volume":"40","author":"Steinberg","year":"2017","journal-title":"Diabetes Care"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0836","article-title":"Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial","volume":"40","author":"Smits","year":"2017","journal-title":"Diabetes Care"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-009-1515-4","article-title":"Biochemical and Histological Effects of Exendin-4 (Exenatide) on the Rat Pancreas","volume":"53","author":"Nachnani","year":"2010","journal-title":"Diabetologia"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.2337\/db11-1109","article-title":"Chronic GLP-1 Receptor Activation by Exendin-4 Induces Expansion of Pancreatic Duct Glands in Rats and Accelerates Formation of Dysplastic Lesions and Chronic Pancreatitis in the Kras(G12D) Mouse Model","volume":"61","author":"Gier","year":"2012","journal-title":"Diabetes"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-013-2957-2","article-title":"Glucagon-Like Peptide-1 Receptor Agonist Treatment Reduces Beta Cell Mass in Normoglycaemic Mice","volume":"56","author":"Ellenbroek","year":"2013","journal-title":"Diabetologia"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.2337\/db11-0936","article-title":"The Human GLP-1 Analog Liraglutide and the Pancreas: Evidence for the Absence of Structural Pancreatic Changes in Three Species","volume":"61","author":"Nyborg","year":"2012","journal-title":"Diabetes"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12040","article-title":"No Evidence of Drug-Induced Pancreatitis in Rats Treated With Exenatide for 13 Weeks","volume":"15","author":"Tatarkiewicz","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00182.2012","article-title":"The Effects of 13 Wk of Liraglutide Treatment on Endocrine and Exocrine Pancreas in Male and Female ZDF Rats: A Quantitative and Qualitative Analysis Revealing No Evidence of Drug-Induced Pancreatitis","volume":"303","author":"Vrang","year":"2012","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.2337\/db13-1087","article-title":"The Human GLP-1 Analogs Liraglutide and Semaglutide: Absence of Histopathological Effects on the Pancreas in Nonhuman Primate","volume":"63","author":"Gotfredsen","year":"2014","journal-title":"Diabetes"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1314078","article-title":"Pancreatic Safety of Incretin-Based Drugs\u2013FDA and EMA Assessment","volume":"370","author":"Egan","year":"2014","journal-title":"N Engl J Med"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1210\/en.2009-1272","article-title":"Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation","volume":"151","author":"Bjerre Knudsen","year":"2010","journal-title":"Endocrinology"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2407","article-title":"Glucagon Like Peptide-1 Receptor Expression in the Human Thyroid Glan","volume":"97","author":"Gier","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.106.038679","article-title":"GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting","volume":"48","author":"K\u00f6rner","year":"2007","journal-title":"J Nucl Med"},{"key":"B81","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1210\/en.2012-2124","article-title":"The Glucagon-Like Peptide-1 Receptor\u2013or Not","volume":"154","author":"Pyke","year":"2013","journal-title":"Endocrinology"},{"key":"B82","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/modpathol.2014.113","article-title":"Glucagon-Like-Peptide-1 Receptor Expression in Normal and Diseased Human Thyroid and Pancreas","volume":"28","author":"Waser","year":"2014","journal-title":"Mod Pathol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1956","article-title":"No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Tria","volume":"41","author":"Heged\u00fcs","year":"2018","journal-title":"Diabetes Care"},{"key":"B84","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A Randomized, Controlled Trial of 3.0 Mg of Liraglutide in Weight Managemen","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12373","article-title":"Incretin-Based Therapy and Acute Cholecystitis: A Review of Case Reports and EudraVigilance Spontaneous Adverse Drug Reaction Reporting Database","volume":"41","author":"Pizzimenti","year":"2016","journal-title":"J Clin Pharm Ther"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2020.108087","article-title":"Cholelithiasis in Patients Treated With Glucagon-Like Peptide-1 Receptor: An Updated Meta-Analysis of Randomized Controlled Trials","volume":"161","author":"Nreu","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"key":"B87","unstructured":"Assessment Report \u201cRybelsu\u201d (EM\/95374\/2020)2020"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0415","article-title":"Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Tria","volume":"42","author":"Nauck","year":"2019","journal-title":"Diabetes Care"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabete","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30069-7","article-title":"3 Years of Liraglutide Versus Placebo for Type 2 Diabetes Risk Reduction and Weight Management in Individuals With Prediabetes: A Randomised, Double-Blind Trial","volume":"389","author":"Le Roux","year":"2017","journal-title":"Lancet"},{"key":"B91","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.regpep.2012.08.005","article-title":"Effect of Exenatide on Cholecystokinin-Induced Gallbladder Emptying in Fasting Healthy Subjects","volume":"179","author":"Keller","year":"2012","journal-title":"Regul Pept"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.940","article-title":"Effect of Albiglutide on Cholecystokinin-Induced Gallbladder Emptying in Healthy Individuals: A Randomized Crossover Stud","volume":"57","author":"Shaddinger","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12748","article-title":"Biliary Effects of Liraglutide and Sitagliptin, a 12-Week Randomized Placebo-Controlled Trial in Type 2 Diabetes Patients","volume":"18","author":"Smits","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13420","article-title":"Effects of Liraglutide on Gallbladder Emptying: A Randomized, Placebo-Controlled Trial in Adults With Overweight or Obesity","volume":"20","author":"Nex\u00f8e-Larsen","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.150870","article-title":"Exendin-4, a Glucagon-Like Peptide 1 Receptor Agonist, Protects Cholangiocytes From Apoptosis","volume":"58","author":"Marzioni","year":"2009","journal-title":"Gut"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.04.007","article-title":"Glucagon-Like Peptide-1 and its Receptor Agonist Exendin-4 Modulate Cholangiocyte Adaptive Response to Cholestasis","volume":"133","author":"Marzioni","year":"2007","journal-title":"Gastroenterology"},{"key":"B97","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/eurheartj\/ehy565.P2857","article-title":"P2857Increase in Pulse Rate With Semaglutide did Not Result in Increased Adverse Cardiac Events in Subjects With Type 2 Diabetes in the SUSTAIN 6 Cardiovascular Outcomes Trial","volume":"39","author":"Seufert","year":"2018","journal-title":"Eur Heart J"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjhyper.2004.06.019","article-title":"Prognostic Value of Home Heart Rate for Cardiovascular Mortality in the General Population: The Ohasama Study","volume":"17","author":"Hozawa","year":"2004","journal-title":"Am J Hypertens"},{"key":"B99","doi-asserted-by":"publisher","first-page":"T1","DOI":"10.1530\/JOE-13-0414","article-title":"Effects of Glucagon-Like Peptide 1 on Appetite and Body Weight: Focus on the CNS","volume":"221","author":"van Bloemendaal","year":"2014","journal-title":"J Endocrinol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0772","article-title":"Liraglutide Reduces CNS Activation in Response to Visual Food Cues Only After Short-Term Treatment in Patients With Type 2 Diabete","volume":"39","author":"ten Kulve","year":"2016","journal-title":"Diabetes Care"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13955","article-title":"Semaglutide (SUSTAIN and PIONEER) Reduces Cardiovascular Events in Type 2 Diabetes Across Varying Cardiovascular Risk","volume":"22","author":"Husain","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"B102","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1001\/jama.2016.10260","article-title":"Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fractio","volume":"316","author":"Margulies","year":"2016","journal-title":"JAMA"},{"key":"B103","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/ejhf.657","article-title":"Effect of Liraglutide, a Glucagon-Like Peptide-1 Analogue, on Left Ventricular Function in Stable Chronic Heart Failure Patients With and Without Diabetes (LIVE)-A Multicentre, Double-Blind, Randomised, Placebo-Controlled Trial","volume":"19","author":"Jorsal","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30038-3","article-title":"Glucose-Lowering Drugs or Strategies, Atherosclerotic Cardiovascular Events, and Heart Failure in People With or at Risk of Type 2 Diabetes: An Updated Systematic Review and Meta-Analysis of Randomised Cardiovascular Outcome Trials","volume":"8","author":"Ghosh-Swaby","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04214.x","article-title":"Investigation of the Haemodynamic Effects of Exenatide in Healthy Male Subjects","volume":"74","author":"Mendis","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1530\/EJE-16-0507","article-title":"Heart Rate Acceleration With GLP-1 Receptor Agonists in Type 2 Diabetes Patients: An Acute and 12-Week Randomised, Double-Blind, Placebo-Controlled Trial","volume":"176","author":"Smits","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12843","article-title":"Exenatide Acutely Increases Heart Rate in Parallel With Augmented Sympathetic Nervous System Activation in Healthy Overweight Males","volume":"81","author":"Smits","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1210\/js.2017-00300","article-title":"Long-Acting GLP-1 Receptor Agonist Exenatide Influence on the Autonomic Cardiac Sympatho-Vagal Balanc","volume":"2","author":"Cacciatori","year":"2018","journal-title":"J Endocr Soc"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-1580","article-title":"Effects of Liraglutide on Heart Rate and Heart Rate Variability: A Randomized, Double-Blind, Placebo-Controlled Crossover Stud","volume":"40","author":"Kumarathurai","year":"2017","journal-title":"Diabetes Care"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00153.2008","article-title":"Effects of Glucagon-Like Peptide-1, Yohimbine, and Nitrergic Modulation on Sympathetic and Parasympathetic Activity in Humans","volume":"295","author":"Bharucha","year":"2008","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1437","article-title":"Effects of GLP-1 Receptor Agonists on Heart Rate and the Autonomic Nervous System Using Holter Electrocardiography and Power Spectrum Analysis of Heart Rate Variabilit","volume":"39","author":"Nakatani","year":"2016","journal-title":"Diabetes Care"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2017.08.010","article-title":"The Autonomic Nervous System and Cardiac GLP-1 Receptors Control Heart Rate in Mice","volume":"6","author":"Baggio","year":"2017","journal-title":"Mol Metab"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-018-0442-0","article-title":"No QTc Prolongation With Semaglutide: A Thorough QT Study in Healthy Subject","volume":"9","author":"Demmel","year":"2018","journal-title":"Diabetes Ther"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-010-9423-8","article-title":"Acute Renal Failure When Exenatide is Co-Administered With Diuretics and Angiotensin II Blockers","volume":"32","author":"L\u00f3pez-Ruiz","year":"2010","journal-title":"Pharm World Sci"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02394-2","article-title":"Effects of Glucagon-Like Peptide-1 Receptor Agonists on Fluid Intake in Healthy Volunteers","volume":"70","author":"Winzeler","year":"2020","journal-title":"Endocrine"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1958","article-title":"Liraglutide Promotes Natriuresis But Does Not Increase Circulating Levels of Atrial Natriuretic Peptide in Hypertensive Subjects With Type 2 Diabetes","volume":"38","author":"Lovshin","year":"2015","journal-title":"Diabetes Care"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2017.123","article-title":"GLP-1 and the Kidney: From Physiology to Pharmacology and Outcomes in Diabetes","volume":"13","author":"Muskiet","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-020-00738-9","article-title":"Nephroprotective Effects of GLP-1 Receptor Agonists: Where do We Stand","volume":"33","author":"Mosterd","year":"2020","journal-title":"J Nephrol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14079","article-title":"The Effect of Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide on Cardiovascular and Renal Outcomes Across Baseline Blood Pressure Categories: Analysis of the LEADER and SUSTAIN 6 Trials","volume":"22","author":"Leiter","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.7326\/M20-0864","article-title":"Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabete","volume":"173","author":"Tsapas","year":"2020","journal-title":"Ann Intern Med"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13172","article-title":"Semaglutide, Reduction in Glycated Haemoglobin and the Risk of Diabetic Retinopathy","volume":"20","author":"Vilsb\u00f8ll","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive Blood-Glucose Control With Sulphonylureas or Insulin Compared With Conventional Treatment and Risk of Complications in Patients With Type 2 Diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Grou","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291401","article-title":"The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2016.40.5.354","article-title":"The Effect of Bariatric Surgery on Diabetic Retinopathy: Good, Bad, or Bot","volume":"40","author":"Gorman","year":"2016","journal-title":"Diabetes Metab J"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198408093110604","article-title":"Blood Glucose Control and the Evolution of Diabetic Retinopathy and Albuminuria","volume":"311","year":"1984","journal-title":"N Engl J Med"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.2337\/diab.34.3.S74","article-title":"Two-Year Experience With Continuous Subcutaneous Insulin Infusion in Relation to Retinopathy and Neuropathy","volume":"34","author":"Lauritzen","year":"1985","journal-title":"Diabetes"},{"key":"B128","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/acta.0.115S007","article-title":"Near-Normoglycemia and Late Diabetic Complications. The Oslo Study","volume":"284","author":"Dahl-J\u00f8rgensen","year":"1987","journal-title":"Acta Endocrinol Suppl (Copenh)"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz069","article-title":"Glucagon-Like Peptide 1 Receptor Agonists, Diabetic Retinopathy and Angiogenesis: The AngioSafe Type 2 Diabetes Study","volume":"105","author":"Gaborit","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B130","unstructured":"FDA Briefing Document, Endocrinologic and Metabolic Drugs Advisory Committee Meeting (EMDA)2017"},{"key":"B131","article-title":"Committee for Medicinal Products for Human Use (CHM)","volume-title":"Assessment Report \u201cRybelsus\u201d (EM\/95374\/2020)","year":""},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-018-0428-y","article-title":"A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide With Other GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Previously Receiving Basal Insuli","volume":"9","author":"Witkowski","year":"2018","journal-title":"Diabetes Ther"},{"key":"B133","doi-asserted-by":"publisher","first-page":"e1176822","DOI":"10.1080\/21688370.2016.1176822","article-title":"Safety Concerns Over the Use of Intestinal Permeation Enhancers: A Mini-Review","volume":"4","author":"McCartney","year":"2016","journal-title":"Tissue Barriers"}],"updated-by":[{"DOI":"10.3389\/fendo.2021.786732","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T00:00:00Z","timestamp":1636502400000}}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.645563\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T10:21:43Z","timestamp":1636539703000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.645563\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,7]]},"references-count":133,"alternative-id":["10.3389\/fendo.2021.645563"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.645563","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,7]]},"article-number":"645563"}}